Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18992802 | 0.98 | KDM4A (0.41) | KDM4AKDM4CEPHX1KISS1RKDM4E | |
| SCHEMBL17093613 | 0.92 | KDM4A (0.39) | KDM4AKDM4CKISS1RSIGMAR1KDM4E | |
| SCHEMBL2721332 | 0.84 | PRMT3 (0.37) | KDM4AKDM4CMEN1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL837377 | 0.82 | KDM4A (0.36) | KDM4AKDM4CMEN1HTTKMT2A | |
| SCHEMBL5791555 | 0.81 | EPHX1 (0.39) | EPHX1KDM4EALDH1A1 | |
| SCHEMBL5312463 | 0.81 | EPHX1 (0.39) | EPHX1KDM4EALDH1A1 | |
| SCHEMBL25435994 | 0.80 | MEN1 (0.55) | EPHX1KDM4ESMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL15844713 | 0.80 | SMN1; SMN2 (0.55) | KDM4AEPHX1KDM4EGAASMN1; SMN2 | |
| SCHEMBL15845051 | 0.80 | SMN1; SMN2 (0.55) | KDM4AEPHX1KDM4EGAASMN1; SMN2 | |
| SCHEMBL5791276 | 0.79 | TSHR (0.40) | EPHX1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4A 104/4885KDM4C 293/4885EPHX1 1684/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4A 104/4885KDM4C 293/4885EPHX1 1684/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4A 104/4885KDM4C 293/4885EPHX1 1684/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4A 104/4885KDM4C 293/4885EPHX1 1684/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4A 104/4885KDM4C 293/4885EPHX1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.